Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications

Diabetes, Obesity & Metabolism
J ChenJ Cook

Abstract

The objective of this analysis is to project the long-term impacts on life expectancy and occurrence over 5, 10, and 40 years of microvascular and macrovascular complications of diabetes when using different haemoglobin A1c (HbA1c) thresholds for intensifying treatment of type 2 diabetes. A flexible, discrete-event simulation model has been developed to evaluate alternative treatment strategies based on the United Kingdom Prospective Diabetes Study Outcomes Model. In the present analysis, the model is used to investigate the impact of alternative HbA1c thresholds for treatment intensification ranging from 7.0 to 9.0%. For each intensification strategy, the model is run using 80 simulated patients for each of 1224 patient profiles from the Real-Life Effectiveness and Care Patterns of Diabetes Management study (for a total of 97,920 simulated patients) to project the number of patients who will experience diabetes-related complications over time. The use of lower HbA1c thresholds for intensifying treatment is associated with improved long-term outcomes. When the HbA1c threshold for intensifying therapy from oral treatment to basal insulin (T1) is 7.0% and the threshold for intensifying basal insulin to multiple-dose insulin (T2) ...Continue Reading

References

Nov 6, 2001·Annals of Internal Medicine·L S PhillipsC S Barnes
Dec 28, 2002·Diabetes Care·UNKNOWN American Diabetes Association
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Jun 29, 2004·Diabetes Care·Jonathan B BrownAndrew Perry
Aug 31, 2004·Diabetes Care·UNKNOWN American Diabetes Association Consensus Panel
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group
Jan 29, 2005·Diabetes Care·Richard W GrantUNKNOWN University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team
Aug 16, 2005·The Diabetes Educator·David C ZiemerLawrence S Phillips
Nov 25, 2005·Diabetes Care·Honghong ZhouWilliam H Herman
Feb 2, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·S A Schreiber, A Russmann
Jan 19, 2008·Diabetes, Obesity & Metabolism·R ScottUNKNOWN Sitagliptin Study 801 Group

❮ Previous
Next ❯

Citations

Sep 20, 2012·Environmental Health : a Global Access Science Source·M Patricia FabianJonathan I Levy
Jul 21, 2010·Current Medical Research and Opinion·Y YiK Burslem
Mar 24, 2009·Life Sciences·Wen-Ying ChenFrank Chiahung Mao
Apr 15, 2014·Risk Analysis : an Official Publication of the Society for Risk Analysis·Jonathan I LevyJunenette L Peters
Dec 11, 2013·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Matthew Harris RutbergTheodore Eugene Day
Aug 23, 2018·Journal of Comparative Effectiveness Research·Bin WuHaixiang Wu
Mar 2, 2012·The Journal of Endocrinology·A J ConleyA D Nguyen
Nov 5, 2019·Journal of Behavioral Medicine·Molly B RichardsonJulia M Gohlke
Jul 6, 2019·Journal of Diabetes and Metabolic Disorders·Vivian Saraiva VerasMaria Lúcia Zanetti
Feb 16, 2021·Environmental Health : a Global Access Science Source·Koen F TieskensM Patricia Fabian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Laura TemimeDidier Guillemot
Diabetic Medicine : a Journal of the British Diabetic Association
R DaviesS Brailsford
© 2022 Meta ULC. All rights reserved